%0 Journal Article
%T Cost-Effectiveness of Aspirin Adherence for Secondary Prevention of Cardiovascular Events
%A Laurence M. Djatche
%A Robert D. Lieberthal
%A Stefan Varga
%J Archive of "PharmacoEconomics Open".
%D 2018
%R 10.1007/s41669-018-0075-2
%X Cost-effectiveness model structure. Cost-effectiveness model structure comparing aspirin adherence vs aspirin non-adherence for secondary prevention of CV events. At the decision node (¡õ), patients were assigned as being adherent or non-adherent to aspirin based on the rate found in the literature. Patients entered the decision node with a prior CV event. In each 1-year cycle, patients may experience an event (non-fatal or fatal) or no event if they are alive. This model was applied to a population without co-morbidity (non-diabetic model) and a population with type II diabetes (type II diabetes model). CV cardiovascular, GI gastrointestinal, MI myocardial infarction, PAD peripheral arterial diseas
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6249193/